For half of the downregulated lncRNAs, namely lnc-ACSBG2-1:1 and lnc-BOD1-1:7, -1:8, and -1:9, high lncRNA expression levels correlated with primary therapy outcome success and lower tumor grade, which further suggest potential tumor-suppressing roles. Here, BOD1 is linked to neoplasm.